替格瑞洛与其他P2Y12受体拮抗剂相互转换应用的研究进展
摘要
双联抗血小板治疗是急性冠状动脉综合征(ACS)或经皮冠状动脉介入治疗(PCI)患者的标准化治疗。近10余年氯吡格雷是临床中应用最普遍的P2Y12受体拮抗剂,而新型抗血小板药物的不断问世,为更安全有效的抗血小板治疗提供了新选择。普拉格雷已证明可用于氯吡格雷抵抗的经皮冠状动脉介入治疗患者。
出处
《中华医学杂志》
CAS
CSCD
北大核心
2017年第11期878-880,共3页
National Medical Journal of China
基金
国家“973”重点基础研究发展计划(2015CB554404)
国家自然科学基金(81570388)
北京市自然科学基金(7142048)
参考文献2
-
1邵春丽,颜红兵,乔树宾,唐熠达,慕朝伟,赵汉军,华倚虹,卿平.替格瑞洛相关呼吸困难的调查分析[J].中国介入心脏病学杂志,2015,23(2):85-88. 被引量:23
-
2Marc Laine,Franck Paganelli,Laurent Bonello.P2Y12-ADP receptor antagonists: Days of future and past[J].World Journal of Cardiology,2016,8(5):327-332. 被引量:4
二级参考文献49
-
1Storey RF, Angiolillo OJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (Platelet Inhibition and Patient Outcomes) PLATELET substudy. J Am Coli Cardiol ,2010 ,56: 1456-1462.
-
2Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Eng! J Med,2009,361 :1045-1057.
-
3Gurbel P A, Blinden KP, Butler K, et al. Response to ticagrelorin clopidogrelnonresponders and responders and effectof switching therapies: the RESPOND Study. Circulation, 2010, 121: 1188-1199.
-
4Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST -segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 2011,32: 2999-3054.
-
5Husted S, Emanuelsson H, Heptinstall S, et al. Phannacodynamics, pharmacokinetics , and safety of the oral reversible P2Y 12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J ,2006 ,27: 1038-1047.
-
6Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST -segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coli Cardiol,2007 ,50: 1844-1851.
-
7Gaubert M, Laine M, Richard T, et al. Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients. Int J Cardiol ,2014,173: 120-121.
-
8Storey RF, Bliden KP, Patil SB, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coli Cardiol,201O, 56: 185-193.
-
9Cattaneo M, Faioni EM. Why does ticagrelor induce dyspnea? Thromb Haernost , 2012 ,108 : 1031-1036.
-
10Storey RF, Becker RC, Harrington RA, et al. Characterizationof dyspnoea in PLATO study patients treated with ticagreloror clopidogrel and its association with clinical outcomes. Eur Heart J,2011,32: 2945-2953.
共引文献25
-
1张怡,钱皎,曹爱霖.替格瑞洛致呼吸困难两例并文献分析[J].药学服务与研究,2015,15(3):224-229. 被引量:8
-
2王绪云,席少枝,刘佳,荆晶,陈韵岱,尹彤.冠心病患者替格瑞洛停药原因及停药对临床转归的影响分析[J].中华老年多器官疾病杂志,2016,15(3):231-236. 被引量:13
-
3苏子云,袁叶,田溪,杨秀岭.替格瑞洛相关不良反应的研究进展[J].中国新药杂志,2016,25(8):878-882. 被引量:11
-
4盛兆雪,赵汉军.替格瑞洛相关呼吸困难的机制与诊治[J].心血管病学进展,2016,37(5):508-511. 被引量:7
-
5那静,梁宇.替格瑞洛用于急性冠脉综合征患者疗效与安全性的回顾性评价[J].中国药师,2017,20(3):494-497. 被引量:8
-
6吴浩鑫,黄至斌,卢贵华,王业松.替格瑞洛拮抗ADP抑制的内皮细胞小管形成[J].热带医学杂志,2017,17(2):161-165. 被引量:2
-
7赵民,边原.以上腹痛伴喉咙憋胀为表现的不稳定心绞痛患者1例[J].临床合理用药杂志,2017,10(11):175-176. 被引量:1
-
8刘娟,颜红兵,宋莉,华倚虹,赵汉军,刘臣,周鹏,李建楠,谭宇.稳定性冠心病患者应用替格瑞洛依从性对心血管事件的影响[J].中国介入心脏病学杂志,2017,25(6):301-306. 被引量:10
-
9刘亚梅,韩战营,王徐乐,邱春光,卢文杰,程博.多索茶碱治疗替格瑞洛相关呼吸困难的安全性和有效性分析[J].中国循环杂志,2017,32(9):886-888. 被引量:18
-
10梁进杰,陈协辉.替格瑞洛治疗急性冠脉综合征的临床应用进展[J].中华心脏与心律电子杂志,2017,5(3):171-174. 被引量:2
-
1张银妆,陈碧莲.抗血小板膜P_2Y_(12)受体拮抗剂的研究进展[J].中国临床药理学与治疗学,2013,18(7):824-830. 被引量:8
-
2黄阳,王兵,刘颖,刘登科,王平保.替卡格雷的合成工艺改进[J].合成化学,2015,23(7):650-652. 被引量:4
-
3韩聪凡,冯文化.血栓性疾病抗血小板聚集药物研究进展[J].中国新药杂志,2016,25(12):1363-1369. 被引量:25
-
4陈骁康,王肖龙.血小板P2Y12受体拮抗剂的研究进展[J].中国全科医学,2016,19(15):1837-1840. 被引量:8
-
5周云英,金佳俊,周蓓.肿瘤患者介入治疗后医院获得性感染的因素分析[J].抗感染药学,2015,12(5):666-668.
-
6朱佩,袁晋青.P2Y_(12)受体拮抗剂与质子泵抑制剂相互作用的研究进展[J].心血管病学进展,2015,36(5):570-574. 被引量:3
-
7侯建同,朱伯谦,孔庆玲,鄢高亮,王栋,乔勇,汤成春.替罗非班对急性冠脉综合征合并代谢综合征介入治疗患者的有效性及安全性研究[J].东南大学学报(医学版),2016,35(5):759-762. 被引量:2
-
8郭梦园,赵志刚,孙树森,李新刚.新型口服抗凝药与华法林临床应用的比较[J].药品评价,2015,12(4):24-29. 被引量:12
-
9抗血小板聚集药——坎格雷洛四钠盐[J].药学进展,2009,33(5):230-232. 被引量:2
-
10刘胜男,赵志刚.血小板P2Y_(12)受体拮抗剂临床研究进展[J].中国新药杂志,2012,21(11):1241-1246. 被引量:2